Common Stock SEC Reporting - Current
Contact Info
  • 15245 Shady Grove Road
  • Suite 470
  • Rockville, MD 20850

Business Description

Update Company Profile
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Sep 30, 2016 10-Q
CIK 0000707511
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o
Incorporated In: DE, USA
Year of Inc. 1982
Employees Not Available
Company Officers/Contacts
J.J. Finkelstein President, CEO
Dane Saglio CFO
Lori Smith Administrator
Company Directors
Allan L. Goldstein Chairman
Mauro Bove
Don Elsey
Joseph C. McNay
Company Notes
  • Formerly=Alpha 1 Biomedicals, Inc. until 12-00
Service Providers
Accounting/Auditing Firm
CohnReznick LLP
8045 Leesburg Pike
Suite 240
Vienna, VA, 22182
United States

Legal Counsel
Fredrikson & Byron, P.A.
200 S. Sixth St.
Suite 4000
Minneapolis, MN, 55402
United States

Investor Relations Firm
PCG Advisory Group
535 Fifth Avenue
24th Floor
New York, NY, 10017
United States

RGRX Security Details
Share Structure
Market Value1 $37,268,716 a/o Dec 09, 2016
Authorized Shares 200,000,000 a/o Sep 30, 2016
Outstanding Shares 106,787,151 a/o Nov 11, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 45,819,317 a/o May 14, 2015
Par Value 0.001
Shareholders of Record 745 a/o Apr 11, 2016
Short Selling Data
Short Interest 980 (-73.07%)
Nov 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security